nodes	percent_of_prediction	percent_of_DWPC	metapath
Valproic Acid—UGT1A6—Mycophenolic acid—psoriasis	0.14	0.187	CbGbCtD
Valproic Acid—UGT1A8—Mycophenolate mofetil—psoriasis	0.0908	0.121	CbGbCtD
Valproic Acid—UGT1A10—Mycophenolate mofetil—psoriasis	0.0908	0.121	CbGbCtD
Valproic Acid—UGT1A6—Mycophenolate mofetil—psoriasis	0.0784	0.105	CbGbCtD
Valproic Acid—UGT1A9—Mycophenolic acid—psoriasis	0.0409	0.0546	CbGbCtD
Valproic Acid—UGT2B7—Mycophenolic acid—psoriasis	0.0387	0.0516	CbGbCtD
Valproic Acid—UGT1A9—Mycophenolate mofetil—psoriasis	0.0229	0.0305	CbGbCtD
Valproic Acid—UGT2B7—Mycophenolate mofetil—psoriasis	0.0216	0.0289	CbGbCtD
Valproic Acid—CYP2A6—Methoxsalen—psoriasis	0.0194	0.0258	CbGbCtD
Valproic Acid—SLC16A1—Methotrexate—psoriasis	0.016	0.0213	CbGbCtD
Valproic Acid—CYP2C8—Tazarotene—psoriasis	0.0148	0.0197	CbGbCtD
Valproic Acid—CYP3A5—Beclomethasone—psoriasis	0.0143	0.0191	CbGbCtD
Valproic Acid—CYP1A2—Clobetasol propionate—psoriasis	0.0141	0.0187	CbGbCtD
Valproic Acid—CYP2A6—Prednisolone—psoriasis	0.00941	0.0125	CbGbCtD
Valproic Acid—CYP2B6—Cholecalciferol—psoriasis	0.00835	0.0111	CbGbCtD
Valproic Acid—SLC22A7—Methotrexate—psoriasis	0.00785	0.0105	CbGbCtD
Valproic Acid—CYP1A2—Methoxsalen—psoriasis	0.00739	0.00985	CbGbCtD
Valproic Acid—CYP2C8—Cholecalciferol—psoriasis	0.00632	0.00843	CbGbCtD
Valproic Acid—SLC22A6—Cyclosporine—psoriasis	0.00631	0.00841	CbGbCtD
Valproic Acid—CYP3A5—Mycophenolate mofetil—psoriasis	0.0057	0.0076	CbGbCtD
Valproic Acid—CYP2A6—Dexamethasone—psoriasis	0.00555	0.0074	CbGbCtD
Valproic Acid—CYP2C8—Mycophenolate mofetil—psoriasis	0.00548	0.00731	CbGbCtD
Valproic Acid—CYP2C19—Cholecalciferol—psoriasis	0.0053	0.00707	CbGbCtD
Valproic Acid—CYP3A4—Calcitriol—psoriasis	0.00498	0.00663	CbGbCtD
Valproic Acid—SLC22A8—Methotrexate—psoriasis	0.00479	0.00639	CbGbCtD
Valproic Acid—CYP3A5—Hydrocortisone—psoriasis	0.00457	0.0061	CbGbCtD
Valproic Acid—CYP2C9—Cholecalciferol—psoriasis	0.00441	0.00588	CbGbCtD
Valproic Acid—CYP2C8—Hydrocortisone—psoriasis	0.0044	0.00586	CbGbCtD
Valproic Acid—CYP3A5—Cyclosporine—psoriasis	0.00432	0.00576	CbGbCtD
Valproic Acid—CYP2C8—Cyclosporine—psoriasis	0.00415	0.00554	CbGbCtD
Valproic Acid—CYP3A4—Methoxsalen—psoriasis	0.00387	0.00516	CbGbCtD
Valproic Acid—CYP2C19—Prednisone—psoriasis	0.00368	0.0049	CbGbCtD
Valproic Acid—CYP2B6—Dexamethasone—psoriasis	0.00361	0.00481	CbGbCtD
Valproic Acid—CYP2C19—Cyclosporine—psoriasis	0.00348	0.00465	CbGbCtD
Valproic Acid—SLC22A6—Methotrexate—psoriasis	0.00334	0.00445	CbGbCtD
Valproic Acid—CYP2C9—Cyclosporine—psoriasis	0.0029	0.00386	CbGbCtD
Valproic Acid—CYP3A5—Dexamethasone—psoriasis	0.00284	0.00379	CbGbCtD
Valproic Acid—CYP2C8—Dexamethasone—psoriasis	0.00274	0.00365	CbGbCtD
Valproic Acid—CYP3A4—Cholecalciferol—psoriasis	0.00256	0.00342	CbGbCtD
Valproic Acid—CYP2C19—Dexamethasone—psoriasis	0.00229	0.00306	CbGbCtD
Valproic Acid—CYP3A4—Mycophenolate mofetil—psoriasis	0.00222	0.00296	CbGbCtD
Valproic Acid—CYP3A4—Triamcinolone—psoriasis	0.00222	0.00296	CbGbCtD
Valproic Acid—HDAC2—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.00218	0.953	CbGdCrCtD
Valproic Acid—CYP2C9—Dexamethasone—psoriasis	0.00191	0.00254	CbGbCtD
Valproic Acid—CYP3A4—Betamethasone—psoriasis	0.00191	0.00254	CbGbCtD
Valproic Acid—CYP3A4—Prednisolone—psoriasis	0.00188	0.00251	CbGbCtD
Valproic Acid—CYP3A4—Hydrocortisone—psoriasis	0.00178	0.00238	CbGbCtD
Valproic Acid—CYP3A4—Prednisone—psoriasis	0.00178	0.00237	CbGbCtD
Valproic Acid—CYP3A4—Cyclosporine—psoriasis	0.00168	0.00225	CbGbCtD
Valproic Acid—CYP3A4—Dexamethasone—psoriasis	0.00111	0.00148	CbGbCtD
Valproic Acid—HDAC2—Levonorgestrel—Hydrocortisone—psoriasis	0.000108	0.0472	CbGdCrCtD
Valproic Acid—HDAC9—SIDS Susceptibility Pathways—TNF—psoriasis	7.96e-05	0.00141	CbGpPWpGaD
Valproic Acid—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	7.87e-05	0.00139	CbGpPWpGaD
Valproic Acid—HDAC2—Regulation of nuclear SMAD2/3 signaling—JUN—psoriasis	7.79e-05	0.00138	CbGpPWpGaD
Valproic Acid—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	7.72e-05	0.00137	CbGpPWpGaD
Valproic Acid—HDAC2—Glucocorticoid receptor regulatory network—JUN—psoriasis	7.71e-05	0.00136	CbGpPWpGaD
Valproic Acid—CYP1A2—Biological oxidations—CYP2S1—psoriasis	7.63e-05	0.00135	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling events mediated by HDAC Class I—STAT3—psoriasis	7.57e-05	0.00134	CbGpPWpGaD
Valproic Acid—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	7.53e-05	0.00133	CbGpPWpGaD
Valproic Acid—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	7.51e-05	0.00133	CbGpPWpGaD
Valproic Acid—HDAC2—p75 NTR receptor-mediated signalling—NFKB1—psoriasis	7.42e-05	0.00131	CbGpPWpGaD
Valproic Acid—HDAC2—Glucocorticoid receptor regulatory network—NFKB1—psoriasis	7.42e-05	0.00131	CbGpPWpGaD
Valproic Acid—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	7.4e-05	0.00131	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—NDUFA5—psoriasis	7.3e-05	0.00129	CbGpPWpGaD
Valproic Acid—SLC16A1—Hemostasis—ITGAL—psoriasis	7.23e-05	0.00128	CbGpPWpGaD
Valproic Acid—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	6.92e-05	0.00122	CbGpPWpGaD
Valproic Acid—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.64e-05	0.00117	CbGpPWpGaD
Valproic Acid—HDAC2—Hemostasis—ITGAL—psoriasis	6.61e-05	0.00117	CbGpPWpGaD
Valproic Acid—CYP1A2—Tryptophan metabolism—CAT—psoriasis	6.58e-05	0.00116	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling events mediated by HDAC Class I—TNF—psoriasis	6.55e-05	0.00116	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—NDUFA5—psoriasis	6.5e-05	0.00115	CbGpPWpGaD
Valproic Acid—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	6.46e-05	0.00114	CbGpPWpGaD
Valproic Acid—HDAC9—SIDS Susceptibility Pathways—IL6—psoriasis	6.43e-05	0.00114	CbGpPWpGaD
Valproic Acid—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	6.37e-05	0.00113	CbGpPWpGaD
Valproic Acid—ACADSB—Metabolism—CAT—psoriasis	6.3e-05	0.00111	CbGpPWpGaD
Valproic Acid—HDAC2—Neural Crest Differentiation—NFKB1—psoriasis	6.28e-05	0.00111	CbGpPWpGaD
Valproic Acid—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.28e-05	0.00111	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—CYP2S1—psoriasis	6.2e-05	0.0011	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling by NOTCH—JUN—psoriasis	6.14e-05	0.00109	CbGpPWpGaD
Valproic Acid—HDAC2—Circadian rythm related genes—LEP—psoriasis	6.09e-05	0.00108	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—NDUFA5—psoriasis	6.07e-05	0.00107	CbGpPWpGaD
Valproic Acid—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	6.06e-05	0.00107	CbGpPWpGaD
Valproic Acid—SLC16A1—Transmembrane transport of small molecules—CP—psoriasis	6.04e-05	0.00107	CbGpPWpGaD
Valproic Acid—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	5.93e-05	0.00105	CbGpPWpGaD
Valproic Acid—CYP3A4—Biological oxidations—CYP2S1—psoriasis	5.89e-05	0.00104	CbGpPWpGaD
Valproic Acid—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	5.81e-05	0.00103	CbGpPWpGaD
Valproic Acid—SLC16A1—Transmembrane transport of small molecules—CARM1—psoriasis	5.77e-05	0.00102	CbGpPWpGaD
Valproic Acid—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	5.73e-05	0.00101	CbGpPWpGaD
Valproic Acid—HDAC2—Circadian rythm related genes—NOS2—psoriasis	5.68e-05	0.001	CbGpPWpGaD
Valproic Acid—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.67e-05	0.001	CbGpPWpGaD
Valproic Acid—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	5.65e-05	0.000999	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—CCL20—psoriasis	5.6e-05	0.000991	CbGpPWpGaD
Valproic Acid—SLC22A7—Transmembrane transport of small molecules—CP—psoriasis	5.59e-05	0.000989	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—CYP2S1—psoriasis	5.53e-05	0.000978	CbGpPWpGaD
Valproic Acid—UGT1A8—Metabolism—CARM1—psoriasis	5.38e-05	0.000951	CbGpPWpGaD
Valproic Acid—OGDH—Metabolism—CAT—psoriasis	5.36e-05	0.000947	CbGpPWpGaD
Valproic Acid—SLC22A7—Transmembrane transport of small molecules—CARM1—psoriasis	5.34e-05	0.000944	CbGpPWpGaD
Valproic Acid—HDAC2—Circadian rythm related genes—PPARG—psoriasis	5.31e-05	0.000939	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—NDUFA5—psoriasis	5.3e-05	0.000938	CbGpPWpGaD
Valproic Acid—SLC22A5—Transmembrane transport of small molecules—CP—psoriasis	5.2e-05	0.000919	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—CYP2S1—psoriasis	5.16e-05	0.000912	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—NDUFA5—psoriasis	5.16e-05	0.000912	CbGpPWpGaD
Valproic Acid—HDAC2—Glucocorticoid receptor regulatory network—TP53—psoriasis	5.09e-05	0.0009	CbGpPWpGaD
Valproic Acid—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.08e-05	0.000899	CbGpPWpGaD
Valproic Acid—HDAC2—Direct p53 effectors—JUN—psoriasis	5.03e-05	0.000889	CbGpPWpGaD
Valproic Acid—SLC22A5—Transmembrane transport of small molecules—CARM1—psoriasis	4.96e-05	0.000877	CbGpPWpGaD
Valproic Acid—ACADSB—Metabolism—APOE—psoriasis	4.89e-05	0.000866	CbGpPWpGaD
Valproic Acid—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	4.84e-05	0.000857	CbGpPWpGaD
Valproic Acid—UGT2B15—Metabolism—CARM1—psoriasis	4.7e-05	0.000832	CbGpPWpGaD
Valproic Acid—SLC22A8—Transmembrane transport of small molecules—CP—psoriasis	4.7e-05	0.000831	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—HCAR2—psoriasis	4.68e-05	0.000827	CbGpPWpGaD
Valproic Acid—HDAC2—Glucocorticoid receptor regulatory network—IL6—psoriasis	4.66e-05	0.000824	CbGpPWpGaD
Valproic Acid—Body temperature increased—Cyclosporine—psoriasis	4.62e-05	0.000242	CcSEcCtD
Valproic Acid—Anxiety—Betamethasone—psoriasis	4.61e-05	0.000241	CcSEcCtD
Valproic Acid—Anxiety—Dexamethasone—psoriasis	4.61e-05	0.000241	CcSEcCtD
Valproic Acid—Vomiting—Mycophenolic acid—psoriasis	4.59e-05	0.00024	CcSEcCtD
Valproic Acid—Discomfort—Dexamethasone—psoriasis	4.57e-05	0.000239	CcSEcCtD
Valproic Acid—Discomfort—Betamethasone—psoriasis	4.57e-05	0.000239	CcSEcCtD
Valproic Acid—Dyspepsia—Hydrocortisone—psoriasis	4.57e-05	0.000239	CcSEcCtD
Valproic Acid—Haemoglobin—Methotrexate—psoriasis	4.57e-05	0.000239	CcSEcCtD
Valproic Acid—Rash—Mycophenolic acid—psoriasis	4.55e-05	0.000238	CcSEcCtD
Valproic Acid—Dermatitis—Mycophenolic acid—psoriasis	4.55e-05	0.000238	CcSEcCtD
Valproic Acid—Pain—Prednisolone—psoriasis	4.55e-05	0.000238	CcSEcCtD
Valproic Acid—Haemorrhage—Methotrexate—psoriasis	4.55e-05	0.000238	CcSEcCtD
Valproic Acid—Urticaria—Mycophenolate mofetil—psoriasis	4.53e-05	0.000237	CcSEcCtD
Valproic Acid—Headache—Mycophenolic acid—psoriasis	4.53e-05	0.000237	CcSEcCtD
Valproic Acid—Decreased appetite—Hydrocortisone—psoriasis	4.51e-05	0.000236	CcSEcCtD
Valproic Acid—Pharyngitis—Methotrexate—psoriasis	4.51e-05	0.000236	CcSEcCtD
Valproic Acid—CYP2C18—Metabolism—CYP2S1—psoriasis	4.51e-05	0.000797	CbGpPWpGaD
Valproic Acid—Abdominal pain—Mycophenolate mofetil—psoriasis	4.51e-05	0.000236	CcSEcCtD
Valproic Acid—Body temperature increased—Mycophenolate mofetil—psoriasis	4.51e-05	0.000236	CcSEcCtD
Valproic Acid—Urinary tract disorder—Methotrexate—psoriasis	4.49e-05	0.000235	CcSEcCtD
Valproic Acid—SLC22A8—Transmembrane transport of small molecules—CARM1—psoriasis	4.48e-05	0.000793	CbGpPWpGaD
Valproic Acid—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.48e-05	0.000235	CcSEcCtD
Valproic Acid—Fatigue—Hydrocortisone—psoriasis	4.48e-05	0.000234	CcSEcCtD
Valproic Acid—Vision blurred—Prednisone—psoriasis	4.46e-05	0.000234	CcSEcCtD
Valproic Acid—Urethral disorder—Methotrexate—psoriasis	4.46e-05	0.000233	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.46e-05	0.000233	CcSEcCtD
Valproic Acid—Pain—Hydrocortisone—psoriasis	4.44e-05	0.000233	CcSEcCtD
Valproic Acid—Oedema—Dexamethasone—psoriasis	4.44e-05	0.000232	CcSEcCtD
Valproic Acid—Anaphylactic shock—Dexamethasone—psoriasis	4.44e-05	0.000232	CcSEcCtD
Valproic Acid—Anaphylactic shock—Betamethasone—psoriasis	4.44e-05	0.000232	CcSEcCtD
Valproic Acid—Oedema—Betamethasone—psoriasis	4.44e-05	0.000232	CcSEcCtD
Valproic Acid—Insomnia—Triamcinolone—psoriasis	4.42e-05	0.000232	CcSEcCtD
Valproic Acid—Infection—Betamethasone—psoriasis	4.41e-05	0.000231	CcSEcCtD
Valproic Acid—Infection—Dexamethasone—psoriasis	4.41e-05	0.000231	CcSEcCtD
Valproic Acid—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	4.4e-05	0.000778	CbGpPWpGaD
Valproic Acid—Ill-defined disorder—Prednisone—psoriasis	4.39e-05	0.00023	CcSEcCtD
Valproic Acid—Paraesthesia—Triamcinolone—psoriasis	4.39e-05	0.00023	CcSEcCtD
Valproic Acid—UGT2B7—Metabolism—CYP2S1—psoriasis	4.39e-05	0.000776	CbGpPWpGaD
Valproic Acid—Feeling abnormal—Prednisolone—psoriasis	4.38e-05	0.000229	CcSEcCtD
Valproic Acid—Visual impairment—Methotrexate—psoriasis	4.38e-05	0.000229	CcSEcCtD
Valproic Acid—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.38e-05	0.000775	CbGpPWpGaD
Valproic Acid—Anaemia—Prednisone—psoriasis	4.38e-05	0.000229	CcSEcCtD
Valproic Acid—Dyspnoea—Triamcinolone—psoriasis	4.36e-05	0.000228	CcSEcCtD
Valproic Acid—Nervous system disorder—Dexamethasone—psoriasis	4.35e-05	0.000228	CcSEcCtD
Valproic Acid—Nervous system disorder—Betamethasone—psoriasis	4.35e-05	0.000228	CcSEcCtD
Valproic Acid—Agitation—Prednisone—psoriasis	4.35e-05	0.000228	CcSEcCtD
Valproic Acid—Thrombocytopenia—Betamethasone—psoriasis	4.34e-05	0.000227	CcSEcCtD
Valproic Acid—Thrombocytopenia—Dexamethasone—psoriasis	4.34e-05	0.000227	CcSEcCtD
Valproic Acid—Tachycardia—Dexamethasone—psoriasis	4.33e-05	0.000227	CcSEcCtD
Valproic Acid—Tachycardia—Betamethasone—psoriasis	4.33e-05	0.000227	CcSEcCtD
Valproic Acid—Angioedema—Prednisone—psoriasis	4.33e-05	0.000227	CcSEcCtD
Valproic Acid—Hypersensitivity—Cyclosporine—psoriasis	4.31e-05	0.000225	CcSEcCtD
Valproic Acid—Dyspepsia—Triamcinolone—psoriasis	4.3e-05	0.000225	CcSEcCtD
Valproic Acid—Erythema multiforme—Methotrexate—psoriasis	4.3e-05	0.000225	CcSEcCtD
Valproic Acid—Nausea—Mycophenolic acid—psoriasis	4.29e-05	0.000225	CcSEcCtD
Valproic Acid—Hyperhidrosis—Betamethasone—psoriasis	4.29e-05	0.000225	CcSEcCtD
Valproic Acid—Hyperhidrosis—Dexamethasone—psoriasis	4.29e-05	0.000225	CcSEcCtD
Valproic Acid—HDAC2—Signaling by NGF—NFKBIA—psoriasis	4.28e-05	0.000757	CbGpPWpGaD
Valproic Acid—Feeling abnormal—Hydrocortisone—psoriasis	4.28e-05	0.000224	CcSEcCtD
Valproic Acid—HDAC2—Cell Cycle—TP53—psoriasis	4.28e-05	0.000756	CbGpPWpGaD
Valproic Acid—Malaise—Prednisone—psoriasis	4.27e-05	0.000224	CcSEcCtD
Valproic Acid—ACADSB—Metabolism—PPARG—psoriasis	4.26e-05	0.000754	CbGpPWpGaD
Valproic Acid—Vertigo—Prednisone—psoriasis	4.25e-05	0.000223	CcSEcCtD
Valproic Acid—Eye disorder—Methotrexate—psoriasis	4.25e-05	0.000222	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Hydrocortisone—psoriasis	4.25e-05	0.000222	CcSEcCtD
Valproic Acid—Tinnitus—Methotrexate—psoriasis	4.24e-05	0.000222	CcSEcCtD
Valproic Acid—Anorexia—Betamethasone—psoriasis	4.23e-05	0.000221	CcSEcCtD
Valproic Acid—Anorexia—Dexamethasone—psoriasis	4.23e-05	0.000221	CcSEcCtD
Valproic Acid—Urticaria—Prednisolone—psoriasis	4.22e-05	0.000221	CcSEcCtD
Valproic Acid—Fatigue—Triamcinolone—psoriasis	4.22e-05	0.000221	CcSEcCtD
Valproic Acid—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.2e-05	0.00022	CcSEcCtD
Valproic Acid—Asthenia—Cyclosporine—psoriasis	4.19e-05	0.00022	CcSEcCtD
Valproic Acid—UGT1A9—Metabolism—NDUFA5—psoriasis	4.19e-05	0.000741	CbGpPWpGaD
Valproic Acid—Pain—Triamcinolone—psoriasis	4.18e-05	0.000219	CcSEcCtD
Valproic Acid—OGDH—Metabolism—APOE—psoriasis	4.16e-05	0.000736	CbGpPWpGaD
Valproic Acid—Hypotension—Betamethasone—psoriasis	4.15e-05	0.000217	CcSEcCtD
Valproic Acid—Hypotension—Dexamethasone—psoriasis	4.15e-05	0.000217	CcSEcCtD
Valproic Acid—Pruritus—Cyclosporine—psoriasis	4.13e-05	0.000216	CcSEcCtD
Valproic Acid—Urticaria—Hydrocortisone—psoriasis	4.13e-05	0.000216	CcSEcCtD
Valproic Acid—Angiopathy—Methotrexate—psoriasis	4.12e-05	0.000216	CcSEcCtD
Valproic Acid—Immune system disorder—Methotrexate—psoriasis	4.11e-05	0.000215	CcSEcCtD
Valproic Acid—Abdominal pain—Hydrocortisone—psoriasis	4.11e-05	0.000215	CcSEcCtD
Valproic Acid—Body temperature increased—Hydrocortisone—psoriasis	4.11e-05	0.000215	CcSEcCtD
Valproic Acid—Mediastinal disorder—Methotrexate—psoriasis	4.1e-05	0.000214	CcSEcCtD
Valproic Acid—Asthenia—Mycophenolate mofetil—psoriasis	4.09e-05	0.000214	CcSEcCtD
Valproic Acid—Hypertension—Prednisone—psoriasis	4.09e-05	0.000214	CcSEcCtD
Valproic Acid—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	4.08e-05	0.000722	CbGpPWpGaD
Valproic Acid—Chills—Methotrexate—psoriasis	4.08e-05	0.000214	CcSEcCtD
Valproic Acid—HDAC2—Signaling by NOTCH—TP53—psoriasis	4.05e-05	0.000717	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—TAGAP—psoriasis	4.05e-05	0.000717	CbGpPWpGaD
Valproic Acid—Musculoskeletal discomfort—Betamethasone—psoriasis	4.04e-05	0.000212	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.04e-05	0.000212	CcSEcCtD
Valproic Acid—Pruritus—Mycophenolate mofetil—psoriasis	4.03e-05	0.000211	CcSEcCtD
Valproic Acid—Myalgia—Prednisone—psoriasis	4.03e-05	0.000211	CcSEcCtD
Valproic Acid—Arthralgia—Prednisone—psoriasis	4.03e-05	0.000211	CcSEcCtD
Valproic Acid—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	4.03e-05	0.000713	CbGpPWpGaD
Valproic Acid—Feeling abnormal—Triamcinolone—psoriasis	4.03e-05	0.000211	CcSEcCtD
Valproic Acid—Anxiety—Prednisone—psoriasis	4.02e-05	0.00021	CcSEcCtD
Valproic Acid—Alopecia—Methotrexate—psoriasis	4.02e-05	0.00021	CcSEcCtD
Valproic Acid—Insomnia—Dexamethasone—psoriasis	4.01e-05	0.00021	CcSEcCtD
Valproic Acid—Insomnia—Betamethasone—psoriasis	4.01e-05	0.00021	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	4e-05	0.00021	CcSEcCtD
Valproic Acid—Diarrhoea—Cyclosporine—psoriasis	4e-05	0.000209	CcSEcCtD
Valproic Acid—Paraesthesia—Dexamethasone—psoriasis	3.98e-05	0.000209	CcSEcCtD
Valproic Acid—Paraesthesia—Betamethasone—psoriasis	3.98e-05	0.000209	CcSEcCtD
Valproic Acid—Discomfort—Prednisone—psoriasis	3.98e-05	0.000209	CcSEcCtD
Valproic Acid—Mental disorder—Methotrexate—psoriasis	3.98e-05	0.000208	CcSEcCtD
Valproic Acid—Malnutrition—Methotrexate—psoriasis	3.96e-05	0.000207	CcSEcCtD
Valproic Acid—UGT1A6—Metabolism—CARM1—psoriasis	3.92e-05	0.000694	CbGpPWpGaD
Valproic Acid—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	3.92e-05	0.000694	CbGpPWpGaD
Valproic Acid—Hypersensitivity—Prednisolone—psoriasis	3.92e-05	0.000205	CcSEcCtD
Valproic Acid—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.91e-05	0.000691	CbGpPWpGaD
Valproic Acid—Dyspepsia—Betamethasone—psoriasis	3.91e-05	0.000204	CcSEcCtD
Valproic Acid—Dyspepsia—Dexamethasone—psoriasis	3.91e-05	0.000204	CcSEcCtD
Valproic Acid—Diarrhoea—Mycophenolate mofetil—psoriasis	3.9e-05	0.000204	CcSEcCtD
Valproic Acid—Urticaria—Triamcinolone—psoriasis	3.88e-05	0.000203	CcSEcCtD
Valproic Acid—Dysgeusia—Methotrexate—psoriasis	3.88e-05	0.000203	CcSEcCtD
Valproic Acid—Body temperature increased—Triamcinolone—psoriasis	3.87e-05	0.000202	CcSEcCtD
Valproic Acid—Dizziness—Cyclosporine—psoriasis	3.86e-05	0.000202	CcSEcCtD
Valproic Acid—Oedema—Prednisone—psoriasis	3.86e-05	0.000202	CcSEcCtD
Valproic Acid—Anaphylactic shock—Prednisone—psoriasis	3.86e-05	0.000202	CcSEcCtD
Valproic Acid—Decreased appetite—Betamethasone—psoriasis	3.86e-05	0.000202	CcSEcCtD
Valproic Acid—Decreased appetite—Dexamethasone—psoriasis	3.86e-05	0.000202	CcSEcCtD
Valproic Acid—Infection—Prednisone—psoriasis	3.84e-05	0.000201	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Dexamethasone—psoriasis	3.83e-05	0.000201	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Betamethasone—psoriasis	3.83e-05	0.000201	CcSEcCtD
Valproic Acid—Back pain—Methotrexate—psoriasis	3.83e-05	0.0002	CcSEcCtD
Valproic Acid—Hypersensitivity—Hydrocortisone—psoriasis	3.83e-05	0.0002	CcSEcCtD
Valproic Acid—Fatigue—Dexamethasone—psoriasis	3.83e-05	0.0002	CcSEcCtD
Valproic Acid—Fatigue—Betamethasone—psoriasis	3.83e-05	0.0002	CcSEcCtD
Valproic Acid—Pain—Dexamethasone—psoriasis	3.79e-05	0.000199	CcSEcCtD
Valproic Acid—Pain—Betamethasone—psoriasis	3.79e-05	0.000199	CcSEcCtD
Valproic Acid—Nervous system disorder—Prednisone—psoriasis	3.79e-05	0.000198	CcSEcCtD
Valproic Acid—Tachycardia—Prednisone—psoriasis	3.77e-05	0.000197	CcSEcCtD
Valproic Acid—Dizziness—Mycophenolate mofetil—psoriasis	3.77e-05	0.000197	CcSEcCtD
Valproic Acid—HDAC2—Circadian rythm related genes—JUN—psoriasis	3.76e-05	0.000666	CbGpPWpGaD
Valproic Acid—Skin disorder—Prednisone—psoriasis	3.75e-05	0.000197	CcSEcCtD
Valproic Acid—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	3.74e-05	0.000662	CbGpPWpGaD
Valproic Acid—Hyperhidrosis—Prednisone—psoriasis	3.74e-05	0.000196	CcSEcCtD
Valproic Acid—Vision blurred—Methotrexate—psoriasis	3.73e-05	0.000195	CcSEcCtD
Valproic Acid—Asthenia—Hydrocortisone—psoriasis	3.73e-05	0.000195	CcSEcCtD
Valproic Acid—Vomiting—Cyclosporine—psoriasis	3.72e-05	0.000195	CcSEcCtD
Valproic Acid—Rash—Cyclosporine—psoriasis	3.68e-05	0.000193	CcSEcCtD
Valproic Acid—Anorexia—Prednisone—psoriasis	3.68e-05	0.000193	CcSEcCtD
Valproic Acid—Dermatitis—Cyclosporine—psoriasis	3.68e-05	0.000193	CcSEcCtD
Valproic Acid—Pruritus—Hydrocortisone—psoriasis	3.67e-05	0.000192	CcSEcCtD
Valproic Acid—Ill-defined disorder—Methotrexate—psoriasis	3.67e-05	0.000192	CcSEcCtD
Valproic Acid—Headache—Cyclosporine—psoriasis	3.66e-05	0.000192	CcSEcCtD
Valproic Acid—Anaemia—Methotrexate—psoriasis	3.66e-05	0.000191	CcSEcCtD
Valproic Acid—Feeling abnormal—Betamethasone—psoriasis	3.66e-05	0.000191	CcSEcCtD
Valproic Acid—Feeling abnormal—Dexamethasone—psoriasis	3.66e-05	0.000191	CcSEcCtD
Valproic Acid—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	3.66e-05	0.000647	CbGpPWpGaD
Valproic Acid—Gastrointestinal pain—Dexamethasone—psoriasis	3.63e-05	0.00019	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Betamethasone—psoriasis	3.63e-05	0.00019	CcSEcCtD
Valproic Acid—Vomiting—Mycophenolate mofetil—psoriasis	3.62e-05	0.00019	CcSEcCtD
Valproic Acid—OGDH—Metabolism—PPARG—psoriasis	3.62e-05	0.000641	CbGpPWpGaD
Valproic Acid—Hypersensitivity—Triamcinolone—psoriasis	3.6e-05	0.000189	CcSEcCtD
Valproic Acid—Rash—Mycophenolate mofetil—psoriasis	3.59e-05	0.000188	CcSEcCtD
Valproic Acid—Dermatitis—Mycophenolate mofetil—psoriasis	3.59e-05	0.000188	CcSEcCtD
Valproic Acid—Headache—Mycophenolate mofetil—psoriasis	3.57e-05	0.000187	CcSEcCtD
Valproic Acid—Malaise—Methotrexate—psoriasis	3.57e-05	0.000187	CcSEcCtD
Valproic Acid—UGT1A9—Metabolism—CYP2S1—psoriasis	3.56e-05	0.00063	CbGpPWpGaD
Valproic Acid—Vertigo—Methotrexate—psoriasis	3.56e-05	0.000186	CcSEcCtD
Valproic Acid—Diarrhoea—Hydrocortisone—psoriasis	3.55e-05	0.000186	CcSEcCtD
Valproic Acid—Leukopenia—Methotrexate—psoriasis	3.54e-05	0.000185	CcSEcCtD
Valproic Acid—Urticaria—Dexamethasone—psoriasis	3.53e-05	0.000185	CcSEcCtD
Valproic Acid—Urticaria—Betamethasone—psoriasis	3.53e-05	0.000185	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Prednisone—psoriasis	3.52e-05	0.000184	CcSEcCtD
Valproic Acid—Dizziness—Prednisolone—psoriasis	3.52e-05	0.000184	CcSEcCtD
Valproic Acid—Asthenia—Triamcinolone—psoriasis	3.51e-05	0.000184	CcSEcCtD
Valproic Acid—Abdominal pain—Dexamethasone—psoriasis	3.51e-05	0.000184	CcSEcCtD
Valproic Acid—Abdominal pain—Betamethasone—psoriasis	3.51e-05	0.000184	CcSEcCtD
Valproic Acid—Body temperature increased—Dexamethasone—psoriasis	3.51e-05	0.000184	CcSEcCtD
Valproic Acid—Body temperature increased—Betamethasone—psoriasis	3.51e-05	0.000184	CcSEcCtD
Valproic Acid—HDAC2—Signaling by NGF—TYK2—psoriasis	3.51e-05	0.00062	CbGpPWpGaD
Valproic Acid—Insomnia—Prednisone—psoriasis	3.5e-05	0.000183	CcSEcCtD
Valproic Acid—HDAC9—Disease—HLA-A—psoriasis	3.48e-05	0.000616	CbGpPWpGaD
Valproic Acid—Nausea—Cyclosporine—psoriasis	3.47e-05	0.000182	CcSEcCtD
Valproic Acid—Paraesthesia—Prednisone—psoriasis	3.47e-05	0.000182	CcSEcCtD
Valproic Acid—Pruritus—Triamcinolone—psoriasis	3.46e-05	0.000181	CcSEcCtD
Valproic Acid—Cough—Methotrexate—psoriasis	3.45e-05	0.000181	CcSEcCtD
Valproic Acid—Dizziness—Hydrocortisone—psoriasis	3.43e-05	0.00018	CcSEcCtD
Valproic Acid—PTGS1—Metabolism—NDUFA5—psoriasis	3.42e-05	0.000604	CbGpPWpGaD
Valproic Acid—Dyspepsia—Prednisone—psoriasis	3.4e-05	0.000178	CcSEcCtD
Valproic Acid—HDAC2—Factors involved in megakaryocyte development and platelet production—TP53—psoriasis	3.4e-05	0.000601	CbGpPWpGaD
Valproic Acid—Nausea—Mycophenolate mofetil—psoriasis	3.39e-05	0.000177	CcSEcCtD
Valproic Acid—Arthralgia—Methotrexate—psoriasis	3.37e-05	0.000176	CcSEcCtD
Valproic Acid—Chest pain—Methotrexate—psoriasis	3.37e-05	0.000176	CcSEcCtD
Valproic Acid—Myalgia—Methotrexate—psoriasis	3.37e-05	0.000176	CcSEcCtD
Valproic Acid—Decreased appetite—Prednisone—psoriasis	3.36e-05	0.000176	CcSEcCtD
Valproic Acid—Rash—Prednisolone—psoriasis	3.35e-05	0.000176	CcSEcCtD
Valproic Acid—Dermatitis—Prednisolone—psoriasis	3.35e-05	0.000175	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.35e-05	0.000175	CcSEcCtD
Valproic Acid—Fatigue—Prednisone—psoriasis	3.33e-05	0.000174	CcSEcCtD
Valproic Acid—Headache—Prednisolone—psoriasis	3.33e-05	0.000174	CcSEcCtD
Valproic Acid—Discomfort—Methotrexate—psoriasis	3.33e-05	0.000174	CcSEcCtD
Valproic Acid—HDAC2—Direct p53 effectors—TP53—psoriasis	3.32e-05	0.000587	CbGpPWpGaD
Valproic Acid—UGT1A8—Metabolism—CAT—psoriasis	3.31e-05	0.000585	CbGpPWpGaD
Valproic Acid—Constipation—Prednisone—psoriasis	3.3e-05	0.000173	CcSEcCtD
Valproic Acid—Vomiting—Hydrocortisone—psoriasis	3.3e-05	0.000173	CcSEcCtD
Valproic Acid—Rash—Hydrocortisone—psoriasis	3.27e-05	0.000171	CcSEcCtD
Valproic Acid—Dermatitis—Hydrocortisone—psoriasis	3.27e-05	0.000171	CcSEcCtD
Valproic Acid—Confusional state—Methotrexate—psoriasis	3.26e-05	0.00017	CcSEcCtD
Valproic Acid—Headache—Hydrocortisone—psoriasis	3.25e-05	0.00017	CcSEcCtD
Valproic Acid—HDAC9—Disease—APOE—psoriasis	3.25e-05	0.000575	CbGpPWpGaD
Valproic Acid—Dizziness—Triamcinolone—psoriasis	3.23e-05	0.000169	CcSEcCtD
Valproic Acid—CYP2A6—Metabolism—NDUFA5—psoriasis	3.23e-05	0.000571	CbGpPWpGaD
Valproic Acid—Anaphylactic shock—Methotrexate—psoriasis	3.23e-05	0.000169	CcSEcCtD
Valproic Acid—Infection—Methotrexate—psoriasis	3.21e-05	0.000168	CcSEcCtD
Valproic Acid—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.19e-05	0.000563	CbGpPWpGaD
Valproic Acid—Feeling abnormal—Prednisone—psoriasis	3.18e-05	0.000167	CcSEcCtD
Valproic Acid—Asthenia—Betamethasone—psoriasis	3.18e-05	0.000167	CcSEcCtD
Valproic Acid—Asthenia—Dexamethasone—psoriasis	3.18e-05	0.000167	CcSEcCtD
Valproic Acid—HDAC2—Gene Expression—CARM1—psoriasis	3.18e-05	0.000562	CbGpPWpGaD
Valproic Acid—Nervous system disorder—Methotrexate—psoriasis	3.17e-05	0.000166	CcSEcCtD
Valproic Acid—Thrombocytopenia—Methotrexate—psoriasis	3.16e-05	0.000166	CcSEcCtD
Valproic Acid—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.16e-05	0.000559	CbGpPWpGaD
Valproic Acid—Gastrointestinal pain—Prednisone—psoriasis	3.16e-05	0.000165	CcSEcCtD
Valproic Acid—Nausea—Prednisolone—psoriasis	3.16e-05	0.000165	CcSEcCtD
Valproic Acid—Pruritus—Dexamethasone—psoriasis	3.14e-05	0.000164	CcSEcCtD
Valproic Acid—Pruritus—Betamethasone—psoriasis	3.14e-05	0.000164	CcSEcCtD
Valproic Acid—Skin disorder—Methotrexate—psoriasis	3.14e-05	0.000164	CcSEcCtD
Valproic Acid—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	3.13e-05	0.000554	CbGpPWpGaD
Valproic Acid—Hyperhidrosis—Methotrexate—psoriasis	3.12e-05	0.000163	CcSEcCtD
Valproic Acid—Vomiting—Triamcinolone—psoriasis	3.11e-05	0.000163	CcSEcCtD
Valproic Acid—Nausea—Hydrocortisone—psoriasis	3.08e-05	0.000162	CcSEcCtD
Valproic Acid—HDAC9—Signaling Pathways—SOCS1—psoriasis	3.08e-05	0.000546	CbGpPWpGaD
Valproic Acid—Rash—Triamcinolone—psoriasis	3.08e-05	0.000161	CcSEcCtD
Valproic Acid—Dermatitis—Triamcinolone—psoriasis	3.08e-05	0.000161	CcSEcCtD
Valproic Acid—Anorexia—Methotrexate—psoriasis	3.08e-05	0.000161	CcSEcCtD
Valproic Acid—Urticaria—Prednisone—psoriasis	3.07e-05	0.000161	CcSEcCtD
Valproic Acid—Headache—Triamcinolone—psoriasis	3.06e-05	0.00016	CcSEcCtD
Valproic Acid—Abdominal pain—Prednisone—psoriasis	3.05e-05	0.00016	CcSEcCtD
Valproic Acid—Body temperature increased—Prednisone—psoriasis	3.05e-05	0.00016	CcSEcCtD
Valproic Acid—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.04e-05	0.000538	CbGpPWpGaD
Valproic Acid—Diarrhoea—Betamethasone—psoriasis	3.04e-05	0.000159	CcSEcCtD
Valproic Acid—Diarrhoea—Dexamethasone—psoriasis	3.04e-05	0.000159	CcSEcCtD
Valproic Acid—UGT1A4—Metabolism—CARM1—psoriasis	3.03e-05	0.000536	CbGpPWpGaD
Valproic Acid—HDAC9—Disease—NOS2—psoriasis	3.03e-05	0.000536	CbGpPWpGaD
Valproic Acid—Hypotension—Methotrexate—psoriasis	3.02e-05	0.000158	CcSEcCtD
Valproic Acid—SLC16A1—Hemostasis—NOS2—psoriasis	2.97e-05	0.000525	CbGpPWpGaD
Valproic Acid—Musculoskeletal discomfort—Methotrexate—psoriasis	2.94e-05	0.000154	CcSEcCtD
Valproic Acid—Dizziness—Dexamethasone—psoriasis	2.93e-05	0.000154	CcSEcCtD
Valproic Acid—Dizziness—Betamethasone—psoriasis	2.93e-05	0.000154	CcSEcCtD
Valproic Acid—Insomnia—Methotrexate—psoriasis	2.92e-05	0.000153	CcSEcCtD
Valproic Acid—PTGS1—Metabolism—CYP2S1—psoriasis	2.9e-05	0.000514	CbGpPWpGaD
Valproic Acid—Nausea—Triamcinolone—psoriasis	2.9e-05	0.000152	CcSEcCtD
Valproic Acid—Paraesthesia—Methotrexate—psoriasis	2.9e-05	0.000152	CcSEcCtD
Valproic Acid—UGT2B15—Metabolism—CAT—psoriasis	2.89e-05	0.000511	CbGpPWpGaD
Valproic Acid—Dyspnoea—Methotrexate—psoriasis	2.88e-05	0.000151	CcSEcCtD
Valproic Acid—Somnolence—Methotrexate—psoriasis	2.87e-05	0.00015	CcSEcCtD
Valproic Acid—Hypersensitivity—Prednisone—psoriasis	2.85e-05	0.000149	CcSEcCtD
Valproic Acid—Dyspepsia—Methotrexate—psoriasis	2.84e-05	0.000149	CcSEcCtD
Valproic Acid—Vomiting—Dexamethasone—psoriasis	2.82e-05	0.000148	CcSEcCtD
Valproic Acid—Vomiting—Betamethasone—psoriasis	2.82e-05	0.000148	CcSEcCtD
Valproic Acid—Decreased appetite—Methotrexate—psoriasis	2.81e-05	0.000147	CcSEcCtD
Valproic Acid—Rash—Betamethasone—psoriasis	2.8e-05	0.000146	CcSEcCtD
Valproic Acid—Rash—Dexamethasone—psoriasis	2.8e-05	0.000146	CcSEcCtD
Valproic Acid—Dermatitis—Betamethasone—psoriasis	2.8e-05	0.000146	CcSEcCtD
Valproic Acid—Dermatitis—Dexamethasone—psoriasis	2.8e-05	0.000146	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Methotrexate—psoriasis	2.79e-05	0.000146	CcSEcCtD
Valproic Acid—Fatigue—Methotrexate—psoriasis	2.78e-05	0.000146	CcSEcCtD
Valproic Acid—Headache—Dexamethasone—psoriasis	2.78e-05	0.000146	CcSEcCtD
Valproic Acid—Headache—Betamethasone—psoriasis	2.78e-05	0.000146	CcSEcCtD
Valproic Acid—Asthenia—Prednisone—psoriasis	2.77e-05	0.000145	CcSEcCtD
Valproic Acid—Pain—Methotrexate—psoriasis	2.76e-05	0.000145	CcSEcCtD
Valproic Acid—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.76e-05	0.000488	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—CYP2S1—psoriasis	2.75e-05	0.000486	CbGpPWpGaD
Valproic Acid—Pruritus—Prednisone—psoriasis	2.73e-05	0.000143	CcSEcCtD
Valproic Acid—HDAC2—Signaling by NGF—NFKB1—psoriasis	2.73e-05	0.000483	CbGpPWpGaD
Valproic Acid—HDAC2—Hemostasis—NOS2—psoriasis	2.71e-05	0.00048	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—CARM1—psoriasis	2.7e-05	0.000478	CbGpPWpGaD
Valproic Acid—Feeling abnormal—Methotrexate—psoriasis	2.66e-05	0.000139	CcSEcCtD
Valproic Acid—Diarrhoea—Prednisone—psoriasis	2.64e-05	0.000138	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Methotrexate—psoriasis	2.64e-05	0.000138	CcSEcCtD
Valproic Acid—Nausea—Betamethasone—psoriasis	2.64e-05	0.000138	CcSEcCtD
Valproic Acid—Nausea—Dexamethasone—psoriasis	2.64e-05	0.000138	CcSEcCtD
Valproic Acid—CYP2B6—Metabolism—NDUFA5—psoriasis	2.61e-05	0.000461	CbGpPWpGaD
Valproic Acid—UGT1A8—Metabolism—APOE—psoriasis	2.57e-05	0.000455	CbGpPWpGaD
Valproic Acid—Urticaria—Methotrexate—psoriasis	2.57e-05	0.000134	CcSEcCtD
Valproic Acid—Dizziness—Prednisone—psoriasis	2.56e-05	0.000134	CcSEcCtD
Valproic Acid—Abdominal pain—Methotrexate—psoriasis	2.55e-05	0.000134	CcSEcCtD
Valproic Acid—Body temperature increased—Methotrexate—psoriasis	2.55e-05	0.000134	CcSEcCtD
Valproic Acid—CYP3A5—Metabolism—NDUFA5—psoriasis	2.55e-05	0.000451	CbGpPWpGaD
Valproic Acid—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	2.53e-05	0.000447	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—CARM1—psoriasis	2.52e-05	0.000445	CbGpPWpGaD
Valproic Acid—HDAC2—Circadian rythm related genes—TP53—psoriasis	2.49e-05	0.00044	CbGpPWpGaD
Valproic Acid—HDAC9—Disease—TYK2—psoriasis	2.48e-05	0.000439	CbGpPWpGaD
Valproic Acid—Vomiting—Prednisone—psoriasis	2.46e-05	0.000129	CcSEcCtD
Valproic Acid—HDAC2—Signaling by NGF—STAT3—psoriasis	2.46e-05	0.000434	CbGpPWpGaD
Valproic Acid—Rash—Prednisone—psoriasis	2.44e-05	0.000128	CcSEcCtD
Valproic Acid—Dermatitis—Prednisone—psoriasis	2.43e-05	0.000127	CcSEcCtD
Valproic Acid—HDAC2—Signaling Pathways—CCL20—psoriasis	2.43e-05	0.00043	CbGpPWpGaD
Valproic Acid—Headache—Prednisone—psoriasis	2.42e-05	0.000127	CcSEcCtD
Valproic Acid—UGT1A6—Metabolism—CAT—psoriasis	2.41e-05	0.000427	CbGpPWpGaD
Valproic Acid—Hypersensitivity—Methotrexate—psoriasis	2.38e-05	0.000125	CcSEcCtD
Valproic Acid—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.37e-05	0.000418	CbGpPWpGaD
Valproic Acid—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.37e-05	0.000418	CbGpPWpGaD
Valproic Acid—Asthenia—Methotrexate—psoriasis	2.32e-05	0.000121	CcSEcCtD
Valproic Acid—Nausea—Prednisone—psoriasis	2.3e-05	0.00012	CcSEcCtD
Valproic Acid—Pruritus—Methotrexate—psoriasis	2.28e-05	0.00012	CcSEcCtD
Valproic Acid—HDAC9—Signaling Pathways—APOE—psoriasis	2.28e-05	0.000403	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—LEP—psoriasis	2.28e-05	0.000403	CbGpPWpGaD
Valproic Acid—HDAC2—Circadian rythm related genes—IL6—psoriasis	2.27e-05	0.000402	CbGpPWpGaD
Valproic Acid—UGT2B15—Metabolism—APOE—psoriasis	2.25e-05	0.000397	CbGpPWpGaD
Valproic Acid—HDAC9—Disease—CD4—psoriasis	2.24e-05	0.000397	CbGpPWpGaD
Valproic Acid—UGT1A8—Metabolism—PPARG—psoriasis	2.24e-05	0.000396	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—CYP2S1—psoriasis	2.22e-05	0.000392	CbGpPWpGaD
Valproic Acid—Diarrhoea—Methotrexate—psoriasis	2.21e-05	0.000116	CcSEcCtD
Valproic Acid—CYP2C8—Metabolism—NDUFA5—psoriasis	2.21e-05	0.00039	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—CARM1—psoriasis	2.2e-05	0.000389	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—CYP2S1—psoriasis	2.17e-05	0.000383	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—CARM1—psoriasis	2.14e-05	0.000379	CbGpPWpGaD
Valproic Acid—Dizziness—Methotrexate—psoriasis	2.14e-05	0.000112	CcSEcCtD
Valproic Acid—HDAC9—Signaling Pathways—NFKBIA—psoriasis	2.12e-05	0.000375	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.06e-05	0.000364	CbGpPWpGaD
Valproic Acid—Vomiting—Methotrexate—psoriasis	2.05e-05	0.000108	CcSEcCtD
Valproic Acid—Rash—Methotrexate—psoriasis	2.04e-05	0.000107	CcSEcCtD
Valproic Acid—Dermatitis—Methotrexate—psoriasis	2.03e-05	0.000107	CcSEcCtD
Valproic Acid—Headache—Methotrexate—psoriasis	2.02e-05	0.000106	CcSEcCtD
Valproic Acid—CYP2C19—Metabolism—NDUFA5—psoriasis	1.97e-05	0.000348	CbGpPWpGaD
Valproic Acid—UGT2B15—Metabolism—PPARG—psoriasis	1.96e-05	0.000346	CbGpPWpGaD
Valproic Acid—Nausea—Methotrexate—psoriasis	1.92e-05	0.0001	CcSEcCtD
Valproic Acid—HDAC2—Gene Expression—VDR—psoriasis	1.9e-05	0.000335	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—CYP2S1—psoriasis	1.88e-05	0.000332	CbGpPWpGaD
Valproic Acid—UGT1A6—Metabolism—APOE—psoriasis	1.88e-05	0.000332	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.87e-05	0.00033	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—CAT—psoriasis	1.86e-05	0.00033	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.84e-05	0.000325	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—NDUFA5—psoriasis	1.8e-05	0.000318	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—CARM1—psoriasis	1.74e-05	0.000308	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—TYK2—psoriasis	1.74e-05	0.000307	CbGpPWpGaD
Valproic Acid—HDAC9—Disease—STAT3—psoriasis	1.74e-05	0.000307	CbGpPWpGaD
Valproic Acid—SLC16A1—Hemostasis—VEGFA—psoriasis	1.72e-05	0.000304	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling by NGF—IL6—psoriasis	1.72e-05	0.000303	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—CYP2S1—psoriasis	1.67e-05	0.000296	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.67e-05	0.000296	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—CAT—psoriasis	1.66e-05	0.000294	CbGpPWpGaD
Valproic Acid—UGT1A6—Metabolism—PPARG—psoriasis	1.63e-05	0.000289	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.63e-05	0.000288	CbGpPWpGaD
Valproic Acid—HDAC2—Hemostasis—VEGFA—psoriasis	1.57e-05	0.000278	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—CAT—psoriasis	1.55e-05	0.000274	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—NDUFA5—psoriasis	1.53e-05	0.000271	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—CYP2S1—psoriasis	1.53e-05	0.00027	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.52e-05	0.000269	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—CXCL8—psoriasis	1.51e-05	0.000268	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—HLA-A—psoriasis	1.51e-05	0.000267	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—APOE—psoriasis	1.45e-05	0.000256	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.43e-05	0.000253	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—CARM1—psoriasis	1.42e-05	0.000251	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—APOE—psoriasis	1.41e-05	0.000249	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—JUN—psoriasis	1.41e-05	0.000249	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—CAT—psoriasis	1.35e-05	0.000239	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—NFKB1—psoriasis	1.35e-05	0.000239	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—CARM1—psoriasis	1.34e-05	0.000237	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—SOCS1—psoriasis	1.34e-05	0.000237	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.33e-05	0.000235	CbGpPWpGaD
Valproic Acid—HDAC2—Gene Expression—PPARG—psoriasis	1.32e-05	0.000234	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—CAT—psoriasis	1.32e-05	0.000233	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—NOS2—psoriasis	1.31e-05	0.000232	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—CYP2S1—psoriasis	1.3e-05	0.000231	CbGpPWpGaD
Valproic Acid—SLC16A1—Hemostasis—TP53—psoriasis	1.3e-05	0.00023	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—APOE—psoriasis	1.29e-05	0.000228	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—PPARG—psoriasis	1.26e-05	0.000223	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—VEGFA—psoriasis	1.23e-05	0.000217	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—STAT3—psoriasis	1.22e-05	0.000215	CbGpPWpGaD
Valproic Acid—HDAC9—Disease—IL6—psoriasis	1.21e-05	0.000215	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—APOE—psoriasis	1.2e-05	0.000213	CbGpPWpGaD
Valproic Acid—HDAC2—Hemostasis—TP53—psoriasis	1.19e-05	0.00021	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—NDUFA5—psoriasis	1.18e-05	0.000209	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—PPARG—psoriasis	1.12e-05	0.000199	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—CARM1—psoriasis	1.08e-05	0.000191	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—TYK2—psoriasis	1.08e-05	0.00019	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—CAT—psoriasis	1.07e-05	0.000189	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—CARM1—psoriasis	1.06e-05	0.000187	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—APOE—psoriasis	1.05e-05	0.000186	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—PPARG—psoriasis	1.05e-05	0.000185	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—APOE—psoriasis	1.02e-05	0.000181	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—CYP2S1—psoriasis	1.01e-05	0.000178	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—APOE—psoriasis	9.87e-06	0.000175	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—LEP—psoriasis	9.87e-06	0.000175	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.83e-06	0.000174	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—CD4—psoriasis	9.73e-06	0.000172	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—TP53—psoriasis	9.28e-06	0.000164	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—NFKBIA—psoriasis	9.2e-06	0.000163	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—PPARG—psoriasis	9.16e-06	0.000162	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—CARM1—psoriasis	9.16e-06	0.000162	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—PPARG—psoriasis	8.91e-06	0.000158	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.78e-06	0.000155	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—CAT—psoriasis	8.73e-06	0.000154	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.57e-06	0.000151	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—IL6—psoriasis	8.5e-06	0.00015	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—APOE—psoriasis	8.32e-06	0.000147	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—CAT—psoriasis	8.25e-06	0.000146	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—CARM1—psoriasis	8.18e-06	0.000145	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	8e-06	0.000142	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.65e-06	0.000135	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—TYK2—psoriasis	7.53e-06	0.000133	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—STAT3—psoriasis	7.53e-06	0.000133	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—CARM1—psoriasis	7.46e-06	0.000132	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—PPARG—psoriasis	7.24e-06	0.000128	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.97e-06	0.000123	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.84e-06	0.000121	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—APOE—psoriasis	6.78e-06	0.00012	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—CAT—psoriasis	6.66e-06	0.000118	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—CXCL8—psoriasis	6.56e-06	0.000116	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—CAT—psoriasis	6.51e-06	0.000115	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—APOE—psoriasis	6.41e-06	0.000113	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—CARM1—psoriasis	6.37e-06	0.000113	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—JUN—psoriasis	6.1e-06	0.000108	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.96e-06	0.000105	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—PPARG—psoriasis	5.91e-06	0.000104	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—NFKB1—psoriasis	5.87e-06	0.000104	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—CAT—psoriasis	5.64e-06	9.97e-05	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—PPARG—psoriasis	5.58e-06	9.88e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—VEGFA—psoriasis	5.33e-06	9.42e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—STAT3—psoriasis	5.27e-06	9.33e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—IL6—psoriasis	5.26e-06	9.31e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—APOE—psoriasis	5.17e-06	9.15e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—APOE—psoriasis	5.06e-06	8.94e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—CAT—psoriasis	5.03e-06	8.9e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—CARM1—psoriasis	4.92e-06	8.7e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—CAT—psoriasis	4.59e-06	8.11e-05	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—PPARG—psoriasis	4.51e-06	7.97e-05	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—PPARG—psoriasis	4.4e-06	7.79e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—APOE—psoriasis	4.38e-06	7.75e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—TP53—psoriasis	4.03e-06	7.12e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—CAT—psoriasis	3.92e-06	6.93e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—APOE—psoriasis	3.91e-06	6.91e-05	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—PPARG—psoriasis	3.81e-06	6.75e-05	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—IL6—psoriasis	3.68e-06	6.52e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—APOE—psoriasis	3.56e-06	6.3e-05	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—PPARG—psoriasis	3.4e-06	6.02e-05	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—PPARG—psoriasis	3.1e-06	5.49e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—APOE—psoriasis	3.05e-06	5.39e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—CAT—psoriasis	3.03e-06	5.35e-05	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—PPARG—psoriasis	2.65e-06	4.69e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—APOE—psoriasis	2.35e-06	4.16e-05	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—PPARG—psoriasis	2.05e-06	3.62e-05	CbGpPWpGaD
